1. At a Glance
The pharmaceutical landscape in India is often perceived as a steady, defensive play, but Pfizer Ltd is currently proving that even the giants must undergo painful skin-shedding to survive. On the surface, the numbers look like a classic case of a multinational corporation (MNC) coasting on past glory. The company reported a Revenue from Operations of ₹2,519.65 Crore for the full year ended March 31, 2026. While the topline grew by roughly 10% compared to the previous year’s ₹2,281.35 Crore, the bottom line tells a story of structural upheaval.
Net Profit for FY26 stood at ₹722.43 Crore, down from ₹767.60 Crore in the prior year. This decline isn’t a result of poor drug sales; it is the price of a massive strategic pivot. Pfizer is effectively outsourcing its feet on the street. In a bold and perhaps risky move, the company signed an exclusive Supply and Marketing Agreement with Cipla Limited for four of its bread-and-butter brands: Corex Dx, Corex LS, Dolonex, and Neksium.
This decision didn’t come cheap. The company took a massive Exceptional Charge of ₹49.16 Crore during the year. A significant chunk of this—₹41.73 Crore—was burned on “personnel separation costs.” In plain English: Pfizer laid off its field force and marketing teams for these brands because it no longer wants to manage the headache of domestic distribution for these specific labels. When a company pays tens of crores to let go of its people, it is either desperate for efficiency or admitted that local players like Cipla can hunt better in the Indian jungle than they can.
Furthermore, the taxman is knocking. The company recently received an Income Tax demand of ₹85.74 Crore for FY23, accompanied by penalty show-cause notices. Add to this the GST demands and penalties totaling over ₹8 Crore received in late 2025, and you have a corporate giant fighting fires on the regulatory front while trying to remodel its house. Investors are watching a transition from a traditional manufacturing and marketing powerhouse to a leaner, perhaps more “royalty and supply” focused entity.
Is this a masterstroke of efficiency or a retreat from the difficult Indian retail market? The market seems undecided, with the stock cooling off significantly from its high of ₹5,993 to the current levels around ₹4,681. The dividend yield remains a modest 0.75%, though the board has recommended a Final Dividend of ₹75 per share.
2. Introduction
Pfizer Ltd is the Indian arm of the global biopharma titan, Pfizer Inc. In India, it holds the prestigious, yet heavy, title of being the 3rd largest multinational pharmaceutical company. It isn’t just a pill manufacturer; it’s a legacy institution that has been part of the Indian healthcare fabric for decades.
The company operates a state-of-the-art manufacturing facility in Goa, which churns out over 3.6 billion tablets annually. Think about that scale for a second. That is nearly 10 million tablets every single day. This plant is the heart of their internal medicine portfolio, producing 186 million Standard Dosage Units across 25 different SKUs.
However, being an MNC in India is a double-edged sword. You have access to world-class R&D from the parent, but you are constantly hit by the National List of Essential Medicines (NLEM) price caps. When the government decides your life-saving drug should cost less, your margins take the hit, not the government’s coffers.
The company’s portfolio is diverse, covering everything from the Prevenar 13 vaccine (a leader in the pneumococcal space) to household names like Gelusil and Becosules. Their distribution network is massive, reaching 2,50,000 retail pharmacies and servicing 300 million patients.
Despite this reach, the last few years have been a rollercoaster. Between FY22 and FY24, revenue actually declined by 16%. Why? A voluntary recall of major brands like Magnex and Zosyn in 2023 due to manufacturing environment concerns, and those pesky NLEM price revisions.
Today, Pfizer is in a “reconstruction” phase. It has divested its Thane land to Zoetis for ₹264 Crore and is now handing over the keys of its most famous respiratory brands to Cipla. It’s a transition from being a “do-it-all” pharma company to a “specialized innovator” that lets others handle the “selling” part.
3. Business Model – WTF Do They Even Do?
If you think Pfizer just sells “blue pills” or “Covid shots,” you’re looking at the global parent, not the Indian entity. Pfizer Ltd in India is essentially a high-end pharmacy and vaccine distributor with a manufacturing backbone.
The Vaccine King
The crown jewel is Prevenar 13. This is the vaccine that prevents pneumonia. In the private market, Pfizer owns a staggering 64.8% value market share. They don’t just sell the vaccine; they create the market. Their “Duty50” initiative targets adults over 50, effectively telling them that aging is fine, but pneumonia isn’t.
The “Legacy” Cabinet
Then there are the brands your parents know: Gelusil for acidity, Becosules for vitamins, and Corex for coughs.
